Advaxis Licenses Novel Antigen for Severe Breast Cancer and Other Tumor Types

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has exclusively licensed the use of antigen ISG15 in Advaxis’ Lm-LLO based immunotherapies from the University of Pennsylvania. This intellectual property resulted from research conducted in Dr. Yvonne Paterson’s laboratory that demonstrated ISG15 was an effective immunological target for the treatment of breast cancer in animal models.

"Targeting ISG15 may represent a therapeutic approach suitable for a population of patients with advanced breast cancer for whom few approved treatments currently exist. The research conducted by Dr. Paterson and colleagues, as well as research conducted at other institutions, suggests that this antigen may have utility in treating other tumor types as well. ISG15 is Advaxis’ first proprietary antigen," said Dr. John Rothman, Executive Vice President, Science & Operations.

About Antigen ISG15

ISG15 is a novel protein associated with numerous cancers. Recently published data demonstrate that Advaxis’ Lm-LLO immunotherapy reduced primary and metastatic breast tumors in an animal model when directed against ISG15. “The Ubiquitin-like Protein, ISG15, is a Novel Tumor-Associated Antigen for Cancer Immunotherapy,” (Wood, LM, Pan, ZK, Seavey, MM, Muthukumaran, G, and Paterson, Y. 2011, Cancer Immunol Immunother).

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to Lm to the cancer itself.

ADXS-HPV, Advaxis’ first construct to reach the clinic is being evaluated in 4 Phase 2 clinical trials for HPV-associated diseases (CIN 2/3, cervical cancer, and head & neck cancer) with over 130 patients dosed to date. Over fifteen (15) distinct constructs are in various stages of development, either developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, and the University of Pennsylvania, among others. For more information please visit: | Facebook | twitter | LinkedIn

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2010, which is available at The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.


Advaxis, Inc.
Diana Moore, 609-452-9814
Director, Investor Relations & Business Development
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical